These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1592542)

  • 21. [Value of the theory of the optimal sampling scheme for bioequivalence studies].
    Tod M; Petitjean O; Nicolas P
    Therapie; 1993; 48(1):7-13. PubMed ID: 8356559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and bioequivalence evaluation of 2 levosulpiride preparations after a single oral dose in healthy male Korean volunteers.
    Cho HY; Moon JD; Lee YB
    Int J Clin Pharmacol Ther; 2004 Mar; 42(3):174-80. PubMed ID: 15049438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies.
    Lacey LF; Keene ON; Duquesnoy C; Bye A
    J Pharm Sci; 1994 Feb; 83(2):212-5. PubMed ID: 8169791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of truncated areas in the assessment of bioequivalence of immediate release formulations of drugs with long half-lives and of Cmax with different dissolution rates.
    Sathe P; Venitz J; Lesko L
    Pharm Res; 1999 Jun; 16(6):939-43. PubMed ID: 10397617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies--moving the "goalposts" or changing the "game".
    Rostami-Hodjegan A; Jackson PR; Tucker GT
    J Pharm Sci; 1994 Nov; 83(11):1554-7. PubMed ID: 7891273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A perspective for biowaivers of human bioequivalence studies on the basis of the combination of the ratio of AUC to the dose and the biopharmaceutics classification system.
    Sakuma S; Tachiki H; Uchiyama H; Fukui Y; Takeuchi N; Kumamoto K; Satoh T; Yamamoto Y; Ishii E; Sakai Y; Takeuchi S; Sugita M; Yamashita S
    Mol Pharm; 2011 Aug; 8(4):1113-9. PubMed ID: 21630662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dissolution modeling of bead formulations and predictions of bioequivalence for a highly soluble, highly permeable drug.
    Sperry DC; Thomas SJ; Lobo E
    Mol Pharm; 2010 Oct; 7(5):1450-7. PubMed ID: 20704266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Finding T
    Han YR; Lee PI; Pang KS
    Drug Metab Dispos; 2018 Nov; 46(11):1796-1804. PubMed ID: 30135243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tmax: an unconfounded metric for rate of absorption in single dose bioequivalence studies.
    Basson RP; Cerimele BJ; DeSante KA; Howey DC
    Pharm Res; 1996 Feb; 13(2):324-8. PubMed ID: 8932457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unique approach for calculation of absorption rate constant.
    Pidgeon C; Pitlick WH
    Res Commun Chem Pathol Pharmacol; 1977 Nov; 18(3):467-75. PubMed ID: 928947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Simulation of bioequivalence study on the base of dissolution curves].
    Grezál G; Vereczkey L
    Acta Pharm Hung; 2012; 82(2):55-9. PubMed ID: 22870777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Why rate of absorption inferences in single dose bioequivalence studies are often inappropriate.
    Basson RP; Ghosh A; Cerimele BJ; DeSante KA; Howey DC
    Pharm Res; 1998 Feb; 15(2):276-9. PubMed ID: 9523315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity of empirical metrics of rate of absorption in bioequivalence studies.
    Ring A; Tothfalusi L; Endrenyi L; Weiss M
    Pharm Res; 2000 May; 17(5):583-8. PubMed ID: 10888310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simulation study of the relationship between variation in bioavailability and clinical equivalence using a direct link model.
    Matsumoto Y; Shimizu M; Ogata H
    Int J Clin Pharmacol Ther; 2005 Jan; 43(1):57-62. PubMed ID: 15704616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Power analyses of moment analysis parameter in bioequivalence tests.
    Kaniwa N; Ogata H; Aoyagi N; Takeda Y; Uchiyama M
    J Pharm Sci; 1989 Dec; 78(12):1020-4. PubMed ID: 2614692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioequivalence of long half-life drugs--informative sampling determination--using truncated area in parallel-designed studies for slow sustained-release formulations.
    El-Tahtawy A; Harrison F; Zirkelbach JF; Jackson AJ
    J Pharm Sci; 2012 Nov; 101(11):4337-46. PubMed ID: 22927120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel multivariate approach for estimating the degree of similarity in bioavailability between two pharmaceutical products.
    Hsu HC; Lu HL; Chan KK
    J Pharm Sci; 1995 Jun; 84(6):768-72. PubMed ID: 7562420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of metabolites in bioequivalency assessment. II. Drugs with linear pharmacokinetics and first-pass effect.
    Chen ML; Jackson AJ
    Pharm Res; 1995 May; 12(5):700-8. PubMed ID: 7479556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of different metrics as indirect measures of rate of drug absorption from extended release dosage forms at steady-state.
    Reppas C; Lacey LF; Keene ON; Macheras P; Bye A
    Pharm Res; 1995 Jan; 12(1):103-7. PubMed ID: 7724468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An alternative approach for assessment of rate of absorption in bioequivalence studies.
    Chen ML
    Pharm Res; 1992 Nov; 9(11):1380-5. PubMed ID: 1475222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.